Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: dwight martin who wrote (21546)	5/29/1998 6:46:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

dwight, I suspect that the Salk agreement covers all formulations of 9-cis retinoic acid, as well as all compounds discovered using the Evans/Salk technology. It was signed in 1988. At that time Ligand was still Progenx, the Ron Evans' technology was being exclusively licensed by Progenx, 9-cis retinoic acid was not known to be a hormone, and future products were largely unknown. I suspect that the one time payment to Salk was based on Progenx/Ligand's first NDA, regardless of product (as long as it came from the Ron Evans/Salk technology).